Peptide evidence guide
Collagen peptides vs BPC-157: two evidence records
Use the side-by-side guide to keep collagen, BPC-157, formulation, route, population, and regulatory status in separate evidence lanes.
TL;DR
Keep collagen and BPC-157 in separate evidence lanes. Match every use claim to the same ingredient, formulation, route, and population.
Key takeaways
- When a Supplement Facts panel is required, FDA's guide requires dietary ingredient names and quantities plus serving information.[1]
- A 2019 collagen paper states that collagen lacks tryptophan and is categorized as an incomplete protein under the PDCAAS protein-quality method.[2]
- FDA found five clinical studies and no human pharmacokinetic data for four proposed routes. Those studies were small and short, and they used rectal, joint, bladder, or intravenous routes.[3]
- The same FDA briefing found no human pharmacokinetic data after oral, subcutaneous, nasal, or transdermal administration.[3]
- FDA's May 11 briefing proposed not adding either form to the 503A Bulks List.[3] The Pharmacy Compounding Advisory Committee (PCAC) separately voted 8-6, with one abstention, to recommend listing each BPC-157 form on July 23.[6][7] FDA says committee recommendations are nonbinding.[8]
- BPC-157 is prohibited in sport under WADA's S0 Non-Approved Substances category.[10]
Collagen labeling and BPC-157 review answer different questions
| Question | Collagen peptides | BPC-157 |
|---|---|---|
| QuestionCommon label lane | Collagen peptidesA dietary product can carry a Supplement Facts panel with ingredient quantities and serving information.[1] | BPC-157FDA evaluated BPC-157-related bulk substances in a July 2026 pharmacy-compounding advisory process.[4][3] |
| QuestionEvidence question | Collagen peptidesAmino-acid composition and dietary protein quality for the stated collagen ingredient.[2] | BPC-157Substance-specific pharmacology, human exposure, safety, and evidence for a proposed drug use.[3] |
| QuestionCurrent evidence boundary | Collagen peptidesThe cited 2019 paper calls collagen an incomplete protein because it lacks tryptophan.[2] | BPC-157FDA found five clinical studies and no human pharmacokinetic data for four proposed routes.[3] |
| QuestionRegulatory record | Collagen peptidesDietary supplement labeling rules govern a product sold in that category.[1] | BPC-157FDA's May 11 briefing proposed not adding either form to the 503A Bulks List.[3] The Pharmacy Compounding Advisory Committee (PCAC) separately voted 8-6, with one abstention, to recommend listing each BPC-157 form on July 23.[6][7] FDA says the recommendation is nonbinding.[8] Neither form appeared in the eCFR list current through July 29. List placement would not mean that a compounded drug made with BPC-157 is FDA approved or endorsed by FDA.[9] BPC-157 is prohibited in sport under WADA's S0 Non-Approved Substances category.[10] |
Collagen evidence starts with the actual ingredient
When required, a Supplement Facts panel lists dietary ingredient names and quantities.[1] That panel provides label identity and quantity, not proof for every health claim attached to a named ingredient.
The 2019 paper used here makes a narrow, useful point about amino-acid composition: collagen lacks the indispensable amino acid tryptophan and is classified as incomplete under PDCAAS.[2]
NutriScore's collagen protein guide follows that protein-quality question without pulling BPC-157 into the answer.
FDA found major gaps in the BPC-157 human record
FDA found five clinical studies and no human pharmacokinetic data for four proposed routes. Those studies were small and short, and they used rectal enema, joint injection, bladder, or intravenous routes. The agency found no human pharmacokinetic data after oral, subcutaneous, nasal, or transdermal administration.[3]
The same briefing also notes U.S. oral-capsule and tablet dietary-supplement marketing for BPC-157. That market presentation does not supply the missing BPC-157 human pharmacokinetic or clinical-safety record for the proposed drug uses and routes.[3]
FDA said the available clinical safety evidence could not define the profile for either the free-base or acetate form. The agency also found the nonclinical safety work too narrow and brief for the proposed uses and routes.[3]
FDA staff and PCAC took opposite positions in July
The FDA introduction for the July 23 and 24 advisory meeting said the briefing packages focused on issues the agency identified but might not include every issue relevant to the committee's recommendations. FDA planned no final determination until committee input and its reviews were complete.[4]
FDA evaluated BPC-157 free base and acetate for ulcerative colitis after the original nominations were withdrawn, proceeding on its own initiative.[3] FDA's May 11 briefing proposed not adding either form to the 503A Bulks List.[3]
The Pharmacy Compounding Advisory Committee (PCAC) separately voted 8-6, with one abstention, to recommend listing each BPC-157 form on July 23.[6][7] FDA's meeting page says the recommendation is nonbinding.[8]
Neither form appeared in 21 CFR 216.23 in the eCFR version current through July 29. That regulation says a compounded drug made with a listed substance is not FDA approved or endorsed by FDA.[9]
Named-substance context outside the FDA record
The pepSmart BPC-157 reference page can provide named-substance context. FDA's briefing and current regulatory records remain the primary sources for the evidence review and list status.[3][8][9]
Related peptide label guides
Peptide label guide
Peptide supplements vs injections: label and record checks
A document-first map for comparing product labels, facility records, FDA records, and certificates. It separates the question each record can answer.
Peptide status guide
What "research use only" means in peptide product labeling
Use the document map to compare seller wording with approval, intended-use, supplier-COA, and human-evidence records.
Peptide document guide
Peptide COA vs Supplement Facts: what each can prove
Use the field-by-field guide to compare a Supplement Facts panel with a supplier COA without treating either document as proof of the other.
Protein quality guide
Does collagen count as protein? The amino acid catch
Open the protein-quality guide for the label questions to ask when comparing collagen with other protein sources.
Sources behind this guide
- Dietary Supplement Labeling Guide: Chapter IV. Nutrition Labeling. U.S. Food and Drug Administration. Content current as of: 2005-04-01.
- Significant Amounts of Functional Collagen Peptides Can Be Incorporated in the Diet While Maintaining Indispensable Amino Acid Balance. MDPI AG. Source date: 2019-05-15.
- July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee - FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate). U.S. Food and Drug Administration. Document date: 2026-05-11.
- July 23-24, 2026 Meeting: FDA Pharmacy Compounding Advisory Committee Briefing Introduction. U.S. Food and Drug Administration. Source date: 2026-07-23.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. Source date: 2026-04-22.
- July 23, 2026 Meeting of the Pharmacy Compounding Advisory Committee (PCAC), BPC-157 free base vote at 4:40. U.S. Food and Drug Administration. Source date: 2026-07-23.
- July 23, 2026 Meeting of the Pharmacy Compounding Advisory Committee (PCAC), BPC-157 acetate vote at 4:51. U.S. Food and Drug Administration. Source date: 2026-07-23.
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. Source date: 2026-07-23.
- 21 CFR 216.23 -- Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act. Electronic Code of Federal Regulations. Source date: 2026-07-29.
- BPC-157: Experimental Peptide Prohibited. U.S. Anti-Doping Agency. Accessed: 2026-09-01.
The July BPC-157 record can change
The dated eCFR list through July 29 did not include either BPC-157 form. Any later change belongs in the current list, not this dated snapshot.[9]
NutriScore has not commissioned independent clinical review of this article.
Read the editorial process and contributor disclosure and the scoring methodology.
Corrections: support@nutriscore.fit.
Sources: 10 entries, all primary canon, last reviewed 2026-08-26.
For research and educational purposes only. Not medical advice.